Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
CNS drugs October 1, 2024 Anton Gomez-Escolar, Daniel Folch-Sanchez, Joanna Stefaniuk et al. 16 citations
Mental health disorders and substance use disorders (SUDs) contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are being explored for SUD treatment but have less clinical evidence than for depression or PTSD. This narrative review discusses current research, therapeutic potential, and safety of psilocybin, LSD, ketamine, MDMA, and ibogaine in SUD treatment. It provides a balanced overview of potential benefits and harms in clinical settings, highlights the need for more research, and points out limitations and challenges to be addressed in future studies.